Skip to content

Study · Non-randomized trial · n = 112 · 2021

3 results

Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.

Pieber TR, Ajala O, Steen O, Dahl D, Hansen LE, Tehranchi R

Diabetes technology & therapeutics1 Nov 2021Cited by 3 (Europe PMC)

PMID34252289 (opens in a new tab)DOI10.1089/dia.2021.0108 (opens in a new tab)PepBankPUB-34252289
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    No treatment-induced or treatment-boosted antidrug antibodies occurred in the repeated-dose dasiglucagon trial.

    In plain wordsThe repeated-dose dasiglucagon trial detected no new or increased antidrug antibodies.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableAntidrug antibodies
    Study

    n = 112

    Analysis
    Primary
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6 mg weekly for three doses · subcutaneous · three consecutive weekly dosesAs given in this study (human).

    Measurements

    ADA incidence
    0
    overall trial

    Source sentences

    Summary
    For the primary immunogenicity endpoint, the overall ADA incidence was zero, as no subject demonstrated any treatment-induced or treatment-boosted ADA response at any time point in this trial involving three consecutive weekly doses of trial drug.
    2 context sentences
    Summary · context
    A total of 112 subjects were randomized 1:1 to receive three subcutaneous weekly doses of either 0.6 mg dasiglucagon or 1.0 mg recombinant glucagon (GlucaGen®) according to a double-blind parallel-group trial design.
    Summary · context
    Subjects were followed for 15 weeks, with a multitiered testing approach planned for assessment of antidrug antibody (ADA) formation.
  2. 02HumanNon-randomized trialSafety outcome

    The repeated-dose dasiglucagon trial reported no unexpected safety findings.

    In plain wordsThe dasiglucagon trial reported no unexpected safety findings.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableUnexpected safety findings
    Study

    n = 112

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.6 mg weekly for three doses · subcutaneous · three consecutive weekly dosesAs given in this study (human).

    Source sentences

    Summary
    There were no unexpected safety findings for the trial.
    2 context sentences
    Summary · context
    A total of 112 subjects were randomized 1:1 to receive three subcutaneous weekly doses of either 0.6 mg dasiglucagon or 1.0 mg recombinant glucagon (GlucaGen®) according to a double-blind parallel-group trial design.
    Summary · context
    Subjects were followed for 15 weeks, with a multitiered testing approach planned for assessment of antidrug antibody (ADA) formation.
  3. 03HumanNon-randomized trialSafety outcome

    No injection site reactions were reported in dasiglucagon recipients with type 1 diabetes.

    In plain wordsDasiglucagon recipients reported no injection site reactions.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableInjection site reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    0.6 mg weekly for three doses · subcutaneous · three consecutive weekly dosesAs given in this study (human).

    Source sentences

    Summary
    No injection site reactions were reported for subjects receiving dasiglucagon.
    2 context sentences
    Summary · context
    A total of 112 subjects were randomized 1:1 to receive three subcutaneous weekly doses of either 0.6 mg dasiglucagon or 1.0 mg recombinant glucagon (GlucaGen®) according to a double-blind parallel-group trial design.
    Summary · context
    Subjects were followed for 15 weeks, with a multitiered testing approach planned for assessment of antidrug antibody (ADA) formation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.